Patients with T2D who undergo kidney transplants are less likely to experience organ failure and mortality if they receive ...

GLP-1 receptor agonists were initially approved for glycaemic control in type 2 diabetes and, subsequently, for bodyweight loss in obesity. Following large-scale trials demonstrating that some GLP-1 ...

THURSDAY, March 6, 2025 (HealthDay News) -- GLP-1 drugs like Ozempic can help kidney transplant patients avoid organ failure and live longer, a new study suggests. The drugs help manage patients ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

A new study reveals that anti-obesity drugs can help kidney transplant recipients with type 2 diabetes reduce the risk of organ failure and increase survival rates. Researchers found that GLP-1 ...

GLP-1 receptor agonists were associated with better graft and patient survival. Clinical trials are needed to confirm these ...

People taking the drugs had a lower risk of organ failure and death However, the drugs were associated with an increased risk ...

"Our study results are the strongest evidence to date that GLP-1 agonist drugs are largely safe and effective tools for addressing type 2 diabetes in kidney transplant recipients," said study lead ...

People taking the drugs had a lower risk of organ failure and death However, the drugs were associated with an increased risk of diabetic retinopathy Originally published on healthday.com, part of ...